About Geftinib 250mg
Discover the new Geftinib 250mg from Cipla Ltd.-a sizzling solution for advanced non-small cell lung cancer (NSCLC) treatment. This lustrous brown, round, film-coated oral tablet brings unmatchable efficacy as an EGFR Tyrosine Kinase Inhibitor. Gefticip is exquisitely packaged in sealed blister strips for ensured quality, ISO and WHO-GMP certified for your peace of mind. Enjoy savings with our regulated pricing, while benefiting from Cipla's trusted manufacturing. Each box contains 30 tablets, prescribed for daily use in adults and dispensed only with a valid prescription.
Targeted Oncology: Efficacy and Features of Geftinib 250mg
Geftinib 250mg is specifically recommended for adults with locally advanced or metastatic NSCLC harboring EGFR mutations. Designed for precise action as an anticancer (allopathic) drug, its oral administration offers convenient dosing. Beyond its exquisite efficacy, Gefticip ensures optimal results in suitable patients, with storage below 30C prolonging its 24-month lifespan. Each tablet is packed with 250mg of active Gefitinib, supporting unmatchable quality standards and general oncological needs across India and global markets.
Swift Delivery & Global Standards: Geftinib 250mg Export
Your order for Geftinib 250mg is swiftly dispatched from India, ensuring timely delivery to your export market via your designated FOB port. Sale price complies with government regulations, granting both affordability and assurance in every transaction. Gefticip stands as WHO-GMP and ISO certified, guaranteeing international quality for traders, suppliers, and distributors. Our efficient export process ensures your consignment arrives securely packaged in blister strips, supporting seamless distribution worldwide.
FAQ's of Geftinib 250mg:
Q: How should Geftinib 250mg be administered for optimal effectiveness?
A: Geftinib 250mg should be taken orally, once daily, either with or without food, as directed by your physician. Consistent administration at the same time each day is recommended for best results.
Q: What are the primary uses and benefits of Geftinib 250mg?
A: Geftinib 250mg is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. Its main benefit lies in its targeted action as an EGFR inhibitor in eligible adults.
Q: When should Geftinib 250mg usage be avoided?
A: Geftinib 250mg is contraindicated in individuals with known hypersensitivity to Gefitinib. It should also be used cautiously if you are taking medications like warfarin, phenytoin, or rifampicin due to potential interactions.
Q: What is the shelf life and recommended storage for Geftinib 250mg?
A: Geftinib 250mg has a lifespan of 24 months and should be stored below 30C, protected from light and moisture, to maintain its efficacy and safety.
Q: Where can I source Geftinib 250mg and what certifications does it have?
A: Geftinib 250mg is manufactured and marketed by Cipla Ltd., India, and is available through authorized distributors, suppliers, and traders. It holds both WHO-GMP and ISO certifications, ensuring quality compliance.
Q: What side effects should I be aware of when taking Geftinib 250mg?
A: Possible side effects include diarrhea, rash, acne, dry skin, and nausea. Always report any adverse reactions to your healthcare provider for proper management.